NHS Cost-Effectiveness Thresholds Boost Drug Ap...

By João L. Carapinha

January 12, 2026

Confirmation of Adjusted Cost-Effectiveness Thresholds for NHS Medicines Evaluations The UK's National Institute for Health and Care Excellence (
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Novartis Drug Pricing Agreement
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Africa Medicine Roadmap: Paving the Way for Sustainable Access to Quality Pha...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Transforming EU Pharmaceutical Legislation: EMA’s Strategic Priorities ...
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...